News and Announcements
Article highlight
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Capital Insights
1
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
2
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
3
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
4
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Executive Interviews
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Company Updates
How to Raise Capital from Wholesale Investors in Australia
Raising capital from wholesale investors is the most efficient path to funding for Australian companies that want to avoid the cost, time, and regulatory burden of producing a full prospectus. Under Section 708 of the Corporations Act 2001, companies can raise capital from investors without a disclosure document, provided specific exemptions are met. This guide […]
Steve Torso: Founder of Wholesale Investor & CapitalHQ
Steve Torso is the Founder and CEO of Wholesale Investor, Australia’s leading private capital marketplace, and CapitalHQ, the AI-powered Capital Engagement Agent platform transforming how companies raise capital and manage investor relationships. Building Australia’s Private Capital Infrastructure Steve co-founded Wholesale Investor in 2008 with a clear thesis: the gap between companies seeking private capital and […]
Wholesale Investor: Australia’s Leading Private Capital Marketplace
Since 2008, Wholesale Investor has been connecting qualified investors with high-growth private companies, fund managers, and alternative investment opportunities across Australia and internationally. With a network of over 45,000 investors, the platform is the largest and most established private capital marketplace in Australasia. What is the Wholesale Investor Platform? Wholesale Investor is a business introduction […]
Wholesale Investor Tests Explained: Net Assets, Income & Product Value
Wholesale Investor Tests Explained Australian law provides multiple pathways for qualifying as a wholesale investor. Each test has different criteria, documentation requirements, and practical implications. This guide provides a detailed breakdown of every qualification test, the evidence required, and the common pitfalls to avoid. Test 1: The Net Assets Test What It Requires Net assets […]
Do I Qualify as a Wholesale Investor? The Complete Self-Assessment
Do I Qualify as a Wholesale Investor? If you are considering investing in private markets in Australia, the first question you need to answer is whether you qualify as a wholesale (or sophisticated) investor. The qualification criteria are set out in the Corporations Act 2001 and are based on financial thresholds rather than investment knowledge […]
![How to Become a Wholesale Investor in Australia [2026 Guide]](https://www.wholesaleinvestor.com/wp-content/uploads/2026/03/how-to-become-797x468.png)
How to Become a Wholesale Investor in Australia [2026 Guide]
How to Become a Wholesale Investor in Australia Becoming a wholesale investor in Australia is not a matter of applying to a regulatory body or passing an exam. It is a classification that flows from meeting specific financial thresholds outlined in the Corporations Act 2001 (Cth). If you meet the criteria, you can be certified […]
Venture Investor Interviews
Australia’s 60,000 Business Succession Crisis: Why Good Companies Will Close Their Doors
The Australian Business Growth Fund identified approximately 162,000 privately held businesses in Australia with revenue between AUD$2 million and AUD$100 million. More than two-thirds are owned by people of retirement age. When surveyed, another two-thirds do not have a succession plan in place. The mathematics are stark. 60,000 businesses owned by someone of retirement age […]
Targeting the Untouchable: The High-Stakes Race to Outsmart ‘Invisible’ Tumors
Percheron Therapeutics is developing the drug HMBD-002 to target the VISTA protein, aiming to make previously “invisible” cancers visible to the immune system. The company is preparing for its critical Phase 2 human trials in 2026 after successful Phase 1 results showed tumor shrinkage.
The 2026 Family Office Briefing: The Great Professionalisation
The days of the family office as a “cottage industry” are over. As complexity overtakes capital, ultra-wealthy families are rapidly professionalising, shifting their focus to direct private markets, integrating AI as an operating system, and hiring non-family, institutional talent. Discover the four strategic imperatives—from navigating the $124 trillion succession crisis to adopting new governance frameworks—that are driving this era of Family Office Professionalisation in 2026.
Australia’s Trillion-Dollar Defence Tech Boom: A Call to Action for Founders
The global defence technology landscape is no longer a niche for the select few. For Australian founders, it represents a monumental, yet frequently underestimated, investment opportunity. Fuelled by escalating geopolitical tensions and a fundamental re-prioritisation of global spending, this sector is experiencing an unprecedented tailwind. According to Steve Baxter, Lead Investor at Beaten Zone Venture […]
Cryptos New Frontier: Institutionalisation, Real-World Assets, and the End of Wild West Investing
The cryptocurrency landscape, once characterised by rapid cycles and speculative frenzy, is undergoing a profound transformation. As global institutions and high-net-worth individuals increasingly look to allocate capital to digital assets, the focus is shifting towards maturity, regulatory clarity, and the integration of blockchain technology with traditional finance. A recent at the Emergence Singapore 2025 panel […]
Moving to Venture Investing 3.0
The next ten years are going to be the most disruptive – and potentially the most profitable – in the history of venture capital. Learn what technologies and techniques you need to adopt in order to become a successful, next-generation private market investor from this keynote presentation by Hatcher+ Managing Partner John Sharp. Looking for […]
Backed By Leading Investment Groups and Family Offices
